文献速递乳房整形与再造

胸肌前直接假体乳房再造:单术者201例连续病例经验

Direct-to-Implant, Prepectoral Breast Reconstruction: A Single-Surgeon Experience with 201 Consecutive Patients.
PubMed 文献 · Plast Reconstr Surg · 2020-01-01

本文回顾性分析单术者201例患者共313侧乳房行即刻胸肌前直接假体乳房再造的结局。需手术干预的并发症发生于24侧乳房(7.7%),轻微并发症发生于23侧乳房(7.3%)。脱细胞真皮基质使用、切口选择及乳房切除术后放疗组间并发症率无显著差异(p>0.05)。

要点

  • 胸肌前直接假体再造总体并发症率较低,需手术干预者为7.7%。
  • 脱细胞真皮基质使用、Wisepattern切口与放疗组间并发症率无显著差异。
  • 脱细胞真皮基质可能与主要并发症相关,放疗可能与轻微并发症相关。

核心结论

  • 胸肌前直接假体乳房再造的并发症率不因脱细胞真皮基质使用、切口选择及乳房切除术后放疗而存在显著差异。
  • 脱细胞真皮基质使用与主要并发症、放疗与轻微并发症之间可能存在关联。

研究设计与样本

  • 回顾性病历分析,纳入2016年6月至2018年6月行胸肌前直接假体乳房再造的患者。
  • 共201例患者、313侧乳房,为文献中最大的单术者直接假体胸肌前队列。

主要发现

  • 需手术干预的并发症发生于24侧乳房(7.7%),轻微并发症发生于23侧乳房(7.3%)。
  • 外侧中部切口用于157侧乳房(50.2%),皮肤缩减Wisepattern用于90侧乳房(28.8%)。
  • 脱细胞真皮基质用于243侧乳房(77.6%),游离乳头移植用于39侧乳房(12.5%),乳房切除术后放疗用于58侧乳房(18.5%)。
  • 脱细胞真皮基质使用与否、Wisepattern与其他切口、放疗与否的并发症率差异均无统计学意义(p>0.05)。

临床怎么用

  • 胸肌前直接假体再造可用于合适患者,脱细胞真皮基质、切口类型及放疗并非绝对禁忌。
  • 术后需关注主要并发症与轻微并发症的分别监测,尤其脱细胞真皮基质使用及放疗患者。

局限性

  • 为单术者回顾性研究,证据等级为治疗性III级,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The resurgence of prepectoral breast reconstruction has brought strict patient inclusion and exclusion criteria by numerous authors. This article provides an overview of a single surgeon's experience with 201 patients, 313 breasts using immediate, direct-to-implant prepectoral breast reconstruction. The article compares surgical outcomes of different patient cohorts to elucidate risk factors that may predispose patients toward developing complications. METHODS: A retrospective chart review was performed, identifying all patients who underwent prepectoral, direct-to-implant breast reconstruction from June of 2016 to June of 2018. RESULTS: A total of 201 patients representing 313 breasts were included. A midlateral incision was used in 157 breasts (50.2 percent), followed by a skin-reducing, Wise-pattern in 90 breasts (28.8 percent). Acellular dermal matrix was used in 243 breasts (77.6 percent), free nipple grafts were used in 39 breasts (12.5 percent), and postmastectomy radiation therapy was used in 58 breasts (18.5 percent). Complications requiring operative intervention occurred in 24 breasts (7.7 percent), and minor complications occurred in 23 breasts (7.3 percent). There were no significant differences in complication rates for (1) acellular dermal matrix use versus non-acellular dermal matrix use, (2) Wise-pattern versus other incision, or (3) postmastectomy radiotherapy (p > 0.05). CONCLUSIONS: This represents the largest single-surgeon, direct-to-implant prepectoral cohort in the literature. Surgical complications did not differ with acellular dermal matrix use, incision selection, and the use of postmastectomy radiation therapy. There may be an association between acellular dermal matrix use and major complications and radiotherapy with minor complications. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Safran T, Al-Halabi B, Viezel-Mathieu A, et al. Direct-to-Implant, Prepectoral Breast Reconstruction: A Single-Surgeon Experience with 201 Consecutive Patients. Plast Reconstr Surg. 2020. PMID: 32221195. doi:10.1097/PRS.0000000000006654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。